{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T14:18:56Z","timestamp":1780496336107,"version":"3.54.1"},"reference-count":52,"publisher":"Association for Research in Vision and Ophthalmology (ARVO)","issue":"6","license":[{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Trans. Vis. Sci. Tech."],"published-print":{"date-parts":[[2026,6,3]]},"DOI":"10.1167\/tvst.15.6.7","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T13:30:45Z","timestamp":1780493445000},"page":"7","source":"Crossref","is-referenced-by-count":0,"title":["Eye Drop Development of Anti-VEGF Therapeutics by Ocular Penetrating Carrier to the Posterior Region of the Eye"],"prefix":"10.1167","volume":"15","author":[{"given":"Venice C.","family":"Chiueh","sequence":"first","affiliation":[{"name":"Department of Research and Development, Wincal Biopharm, Inc., South San Francisco, CA 94080, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda L.","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Research and Development, Wincal Biopharm, Inc., South San Francisco, CA 94080, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Tau","sequence":"additional","affiliation":[{"name":"Department of Research and Development, Wincal Biopharm, Inc., South San Francisco, CA 94080, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxine","family":"Luu","sequence":"additional","affiliation":[{"name":"Department of Research and Development, Wincal Biopharm, Inc., South San Francisco, CA 94080, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph H.","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Research and Development, Wincal Biopharm, Inc., South San Francisco, CA 94080, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"TaeWeon","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Research and Development, Wincal Biopharm, Inc., South San Francisco, CA 94080, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"27","reference":[{"key":"bib1","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.mcna.2021.01.003","article-title":"Age-Related Macular Degeneration","volume":"105","author":"Thomas","year":"2021","journal-title":"Med Clin North Am"},{"issue":"17","key":"bib2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s40662-015-0026-2","article-title":"Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss","volume":"2","author":"Lee","year":"2015","journal-title":"Eye and Vis"},{"key":"bib3","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/S2214-109X(13)70145-1","article-title":"Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis","volume":"2","author":"Wong","year":"2014","journal-title":"Lancet Glob Health"},{"key":"bib4","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1016\/j.ophtha.2021.04.027","article-title":"Global prevalence of diabetic retinopathy and projection of burden through 2045: systematic review and meta-analysis","volume":"128","author":"Teo","year":"2021","journal-title":"Ophthalmology"},{"issue":"6","key":"bib5","first-page":"S81","article-title":"Treatment approaches for neovascular age-related macular degeneration and diabetic macular edema","volume":"29","author":"Almony","year":"2023","journal-title":"Am J Manag Care"},{"issue":"19","key":"bib6","doi-asserted-by":"publisher","first-page":"11769","DOI":"10.3390\/ijms231911769","article-title":"Therapeutic approaches for age-related macular degeneration","volume":"23","author":"Galindo-Camacho","year":"2022","journal-title":"Int J Mol Sci"},{"key":"bib7","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1080\/13548506.2014.936886","article-title":"Experiences of patients undergoing anti-VEGF treatment for neovascular age-related macular degeneration: a systematic review","volume":"20","author":"Boyle","year":"2014","journal-title":"Psychol Health Med"},{"key":"bib8","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/eye.2013.107","article-title":"Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature","volume":"27","author":"Falavarjani","year":"2013","journal-title":"Eye"},{"key":"bib9","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"key":"bib10","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/j.ophtha.2019.03.023","article-title":"Simultaneous inhibition of angiopoietin-2 and vascular endothelial growth factor-A with faricimab in diabetic macular edema","volume":"126","author":"Sahni","year":"2019","journal-title":"Ophthalmology"},{"key":"bib11","first-page":"142","article-title":"Visual acuity outcomes and anti-vascular endothelial growth factor therapy intensity in neovascular age-related macular degeneration patients: a real-world analysis of 49 485 eyes","volume":"127","author":"Ciulla","year":"2020","journal-title":"Ophthalmol Retina"},{"key":"bib12","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.preteyeres.2017.12.002","article-title":"Real-world outcomes in patients with neovascular age-related macular degeneration treated with intravitreal vascular endothelial growth factor inhibitors","volume":"65","author":"Mehta","year":"2018","journal-title":"Prog Ret Eye Res"},{"key":"bib13","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1038\/s41433-024-02998-2","article-title":"Real-world effects of anti-vascular endothelial growth factor injection frequency on visual outcomes in patients with diabetic macular oedema","volume":"38","author":"Payne","year":"2024","journal-title":"Eye"},{"key":"bib14","doi-asserted-by":"publisher","first-page":"e140","DOI":"10.1111\/aos.15725","article-title":"How latonoprost changed glaucoma management","volume":"102","author":"Cordeiro","year":"2024","journal-title":"Acta Ophthalmol"},{"key":"bib15","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1080\/14656566.2020.1795130","article-title":"Current and new pharmacotherapeutic approaches for glaucoma","volume":"21","author":"Shalaby","year":"2020","journal-title":"Expert Opin Pharmacother"},{"key":"bib16","doi-asserted-by":"publisher","first-page":"134","DOI":"10.3390\/pharmaceutics14010134","article-title":"Topical drug delivery to the posterior segment of the eye","volume":"14","author":"Loscher","year":"2022","journal-title":"Pharmaceutics"},{"key":"bib17","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jconrel.2014.06.043","article-title":"Ocular delivery of macromolecules","volume":"0","author":"Kim","year":"2014","journal-title":"J Control Release"},{"key":"bib18","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1021\/acs.jmedchem.7b00237","article-title":"How big is too big for cell permeability","volume":"60","author":"Matsson","year":"2017","journal-title":"J Med Chem"},{"key":"bib19","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1021\/acs.jmedchem.6b01483","article-title":"Nonclassical size dependence of permeation defines bounds for passive adsorption of large drug molecules","volume":"60","author":"Pye","year":"2017","journal-title":"J Med Chem"},{"key":"bib20","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1167\/iovs.16-20072","article-title":"Topical delivery of anti-VEGF drugs to the ocular posterior segment using cell-penetrating peptides","volume":"58","author":"De Cogan","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"bib21","doi-asserted-by":"publisher","first-page":"eabq3104","DOI":"10.1126\/sciadv.abq3104","article-title":"Eye drop-based macromolecular ophthalmic drug delivery for ocular fundus disease treatment","volume":"9","author":"Shen","year":"2023","journal-title":"Sci Adv"},{"issue":"2","key":"bib22","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1167\/iovs.62.2.5","article-title":"VEGFR2 trafficking by KIF13B is a novel therapeutic target for wet age-related macular degeneration","volume":"62","author":"Waters","year":"2021","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"bib23","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/j.biopha.2018.09.097","article-title":"Cell penetrating peptides: a concise review with emphasis on biomedical applications","volume":"108","author":"Derakhshankhah","year":"2018","journal-title":"Biomed Pharmacother"},{"key":"bib24","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/0092-8674(88)90263-2","article-title":"Cellular uptake of the tat protein from human immunodeficiency virus","volume":"55","author":"Frankel","year":"1988","journal-title":"Cell"},{"key":"bib25","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/0092-8674(88)90262-0","article-title":"Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein","volume":"55","author":"Green","year":"1988","journal-title":"Cell"},{"issue":"D1","key":"bib26","doi-asserted-by":"publisher","first-page":"D1090","DOI":"10.1093\/nar\/gkv1266","article-title":"CPPsite 2.0: a repository of experimentally validated cell-penetrating peptides","volume":"44","author":"Agrawal","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"bib27","doi-asserted-by":"publisher","first-page":"697","DOI":"10.3389\/fphar.2020.00697","article-title":"Cell-penetrating peptides in diagnosis and treatment of human diseases: from preclinical research to clinical application","volume":"11","author":"Xie","year":"2020","journal-title":"Front Pharmacol"},{"key":"bib28","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.3390\/cells12071071","article-title":"Ocular delivery of therapeutic agents by cell-penetrating peptides","volume":"12","author":"Nhan","year":"2023","journal-title":"Cells"},{"issue":"1","key":"bib29","doi-asserted-by":"publisher","first-page":"e0227732","DOI":"10.1371\/journal.pone.0227732","article-title":"Histological and immunohistochemical characterization of the porcine ocular surface","volume":"15","author":"Crespo-Moral","year":"2020","journal-title":"PLoS One"},{"key":"bib30","first-page":"2529","article-title":"Porcine sclera: thickness and surface area","volume":"43","author":"Olsen","year":"2002","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"194","key":"bib31","first-page":"e64414","article-title":"Microdissection of the Rodent Eye","author":"Mohan","year":"2023","journal-title":"J Vis Exp"},{"key":"bib32","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1016\/j.xphs.2023.04.006","article-title":"Pharmacokinetics of monoclonal antibody and antibody fragments in the mouse eye following intravitreal administration","volume":"112","author":"Bussing","year":"2023","journal-title":"J Pharm Sci"},{"issue":"3","key":"bib33","doi-asserted-by":"publisher","first-page":"e83","DOI":"10.1002\/cpmo.83","article-title":"Quantitative proteomic profiling of murine ocular tissue and the extracellular environment","volume":"10","author":"Yeung","year":"2020","journal-title":"Curr Protoc Mouse Biol"},{"key":"bib37","doi-asserted-by":"publisher","first-page":"7543","DOI":"10.3390\/ijms24087543","article-title":"Characterization of porcine ocular surface epithelial microenvironment","volume":"24","author":"Polisettie","year":"2023","journal-title":"Int J Mol Sci."},{"issue":"12","key":"bib38","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1167\/tvst.10.12.3","article-title":"Normative data of axial length, retinal thickness measurements, visual evoked potentials, and full-field electroretinography in female, wild-type minipigs","volume":"10","author":"Choi","year":"2021","journal-title":"Transl Vis Sci Technol"},{"key":"bib39","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1038\/nprot.2013.135","article-title":"Laser-induced choroidal neovascularization model to study age-related macular degeneration in mice","volume":"8","author":"Lambert","year":"2013","journal-title":"Nat Protoc"},{"key":"bib40","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1089\/jop.2015.0049","article-title":"A simple optical coherence tomography quantification method for choroidal neovascularization","volume":"31","author":"Sulaiman","year":"2015","journal-title":"J Ocul Pharmacol Ther"},{"key":"bib41","doi-asserted-by":"crossref","first-page":"414729","DOI":"10.1155\/2011\/414729","article-title":"Mechanisms of cellular uptake of cell-penetration peptides","volume":"2011","author":"Madani","year":"2011","journal-title":"J Biophys"},{"key":"bib42","doi-asserted-by":"publisher","first-page":"101","DOI":"10.3762\/bjnano.11.10","article-title":"Internalization mechanisms of cell-penetrating peptides","volume":"11","author":"Ruseska","year":"2020","journal-title":"Beilstein J Nanotechol."},{"key":"bib43","doi-asserted-by":"publisher","first-page":"491","DOI":"10.4049\/jimmunol.174.1.491","article-title":"Role of complement and complement membrane attack complex in laser-induced choroidal neovascularization","volume":"174","author":"Bora","year":"2005","journal-title":"J Immunol"},{"key":"bib44","doi-asserted-by":"publisher","first-page":"5677","DOI":"10.1167\/iovs.07-0156","article-title":"Upregulation of VEGF in murine retina via monocyte recruitment after retinal scatter laser photocoagulation","volume":"48","author":"Itaya","year":"2007","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"bib45","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1167\/iovs.07-1508","article-title":"Increased choroidal neovascularization following laser induction in mice lacking lysyl oxidase-like 1","volume":"49","author":"Yu","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"bib46","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1001\/archophthalmol.2011.210","article-title":"Prevention of experimental choroidal neovascularization and resolution of active lesions by VEGF trap in nonhuman primates","volume":"129","author":"Nork","year":"2011","journal-title":"Arch Ophthalmol"},{"key":"bib47","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.2147\/OPTH.S118409","article-title":"Systemic side effects of eye drops: a pharmacokinetic perspective","volume":"10","author":"Farkouh","year":"2016","journal-title":"Clin Ophthalmol"},{"key":"bib48","doi-asserted-by":"publisher","first-page":"305","DOI":"10.2174\/1874364101711010305","article-title":"A single drop in the eye \u2013 effects on the whole body?","volume":"11","author":"Vaajanen","year":"2017","journal-title":"Open Ophthalmol J"},{"key":"bib49","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.ejpb.2020.06.024","article-title":"PET study of ocular and blood pharmacokinetics of intravitreal bevacizumab and aflibercept in rats","volume":"154","author":"Luaces-Rodriguez","year":"2020","journal-title":"Eur J Pharm Biopharm"},{"issue":"8","key":"bib50","doi-asserted-by":"publisher","first-page":"365","DOI":"10.3390\/pharmaceutics11080365","article-title":"Pharmacokinetics of intravitreal anti-VEGF drugs in age-related macular degeneration","volume":"11","author":"Garcia-Quintanilla","year":"2019","journal-title":"Pharmaceutics"},{"key":"bib51","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1007\/s40123-025-01157-4","article-title":"Systemic effects of intravitreal anti-VEGF therapy: a review of safety across organ systems","volume":"14","author":"Banerjee","year":"2025","journal-title":"Ophthalmol Ther"},{"issue":"1","key":"bib52","doi-asserted-by":"publisher","first-page":"10597","DOI":"10.1038\/s41598-023-37584-1","article-title":"Long-term surveillance provides real-world evidences of safety and effectiveness in intravitreal aflibercept treatment for age-related macular degeneration","volume":"13","author":"Ozawa","year":"2023","journal-title":"Sci Rep"},{"key":"bib34","first-page":"234","article-title":"U-Net: Convolutional networks for biomedical image segmentation","volume-title":"Medical Image Computing and Computer-Assisted Intervention \u2013 MICCAI 2015","author":"Ronneberger","year":"2015"},{"key":"bib35","doi-asserted-by":"crossref","article-title":"torch: Tensors and neural networks with GPU acceleration","author":"Falbel","DOI":"10.32614\/CRAN.package.torch"},{"key":"bib36","doi-asserted-by":"crossref","DOI":"10.32614\/R.manuals","article-title":"R: A language and environment for statistical computing","volume-title":"R Foundation for Statistical Computing;","author":"R Core Team","year":"2025"}],"container-title":["Translational Vision Science & Technology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/tvst.arvojournals.org\/article.aspx?doi=10.1167\/tvst.15.6.7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T13:30:52Z","timestamp":1780493452000},"score":1,"resource":{"primary":{"URL":"http:\/\/tvst.arvojournals.org\/article.aspx?doi=10.1167\/tvst.15.6.7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,3]]},"references-count":52,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6,1]]}},"URL":"https:\/\/doi.org\/10.1167\/tvst.15.6.7","relation":{},"ISSN":["2164-2591"],"issn-type":[{"value":"2164-2591","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,3]]}}}